EE152 Cost-Effectiveness Modeling of Lurbinectedin As a Second-Line Therapy in Patients with Small Cell Lung Cancer (SCLC)
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.455
https://www.valueinhealthjournal.com/article/S1098-3015(23)00555-7/fulltext
Title :
EE152 Cost-Effectiveness Modeling of Lurbinectedin As a Second-Line Therapy in Patients with Small Cell Lung Cancer (SCLC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00555-7&doi=10.1016/j.jval.2023.03.455
First page :
Section Title :
Open access? :
No
Section Order :
11839